TOP TEN perturbations for 38763_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38763_at
Selected probe(set): 230782_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38763_at (230782_at) across 6674 perturbations tested by GENEVESTIGATOR:
skin squamous cell carcinoma study 6 / basal cell carcinoma study 2
Relative Expression (log2-ratio):-3.4754047Number of Samples:4 / 2
| Experimental | skin squamous cell carcinoma study 6 |
| Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC). | |
| Control | basal cell carcinoma study 2 |
| Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC). |
HCC study 9 (alcohol; HBV) / HCC study 9 (HBV)
Relative Expression (log2-ratio):3.101489Number of Samples:3 / 10
| Experimental | HCC study 9 (alcohol; HBV) |
| Liver tissue biopsy sample from patients with alcohol abuse and Hepatitis B infection related hepatocellular carcinoma (HCC) after resection. | |
| Control | HCC study 9 (HBV) |
| Liver tissue biopsy sample from patients with Hepatitis B infection related hepatocellular carcinoma (HCC) after resection. |
pancreatic cancer study 3 (ipmn) / normal pancreas tissue
Relative Expression (log2-ratio):3.0346937Number of Samples:3 / 6
| Experimental | pancreatic cancer study 3 (ipmn) |
| Intraductal papillary mucinous neoplasm from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |
adefovir study 1 (50uM) / vehicle (DMSO) treated HepG2 sample
Relative Expression (log2-ratio):2.8030014Number of Samples:3 / 21
| Experimental | adefovir study 1 (50uM) |
| HepG2 cells treated with compound: adefovir (50uM; CAS no.:106941-25-7) for 24 hours. Adefovir is non-hepatotoxic. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HepG2 sample |
| HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours. |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.6694727Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)
Relative Expression (log2-ratio):-2.6510172Number of Samples:3 / 3
| Experimental | wound healing study 2 (ex vivo; DMSO) |
| Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. | |
| Control | normal skin tissue (ex vivo) |
| Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. |
pancreatic cancer study 3 (ipmn) / pancreatic cancer study 3 (ipma)
Relative Expression (log2-ratio):2.6491814Number of Samples:3 / 6
| Experimental | pancreatic cancer study 3 (ipmn) |
| Intraductal papillary mucinous neoplasm from patients with pancreatic cancer. | |
| Control | pancreatic cancer study 3 (ipma) |
| Intraductal papillary mucinous adenoma from patients with pancreatic cancer. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / tunicamycin study 2 (2ug/ml; HCT 116)
Relative Expression (log2-ratio):-2.6177788Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | tunicamycin study 2 (2ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- |
prostate cancer study 1 (meta.) / benign prostate tissue
Relative Expression (log2-ratio):-2.5361671Number of Samples:6 / 6
| Experimental | prostate cancer study 1 (meta.) |
| Metastatic prostate cancer samples. | |
| Control | benign prostate tissue |
| Benign prostate samples. |
Merkel cell carcinoma study 3 (primary) / basal cell carcinoma study 2
Relative Expression (log2-ratio):-2.5108624Number of Samples:19 / 2
| Experimental | Merkel cell carcinoma study 3 (primary) |
| Primary tumor tissue from the skin of patients with Merkel cell carcinoma. | |
| Control | basal cell carcinoma study 2 |
| Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC). |
Organism: Homo sapiens
Gene: 38763_at
Selected probe(set): 201563_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38763_at (201563_at) across 6674 perturbations tested by GENEVESTIGATOR:
prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)
Relative Expression (log2-ratio):4.987013Number of Samples:3 / 2
| Experimental | prostate cancer study 8 (p. canc) |
| CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (ptasc) |
| CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):4.453725Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample
Relative Expression (log2-ratio):3.9006996Number of Samples:2 / 2
| Experimental | T-cell activation study 3 |
| CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs. | |
| Control | resting CD4 T-lymphocyte (crude fraction) sample |
| Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)
Relative Expression (log2-ratio):3.531722Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal T-cell; 20uM) |
| MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)
Relative Expression (log2-ratio):-3.454461Number of Samples:15 / 5
| Experimental | precursor-B-ALL study 3 (TEL-AML1) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | precursor-B-ALL study 3 (MLL-rearranged) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):-3.4037666Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):-3.2914543Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-3.2827568Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (tularensis Schu S4) |
| Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / tunicamycin study 2 (2ug/ml; HCT 116)
Relative Expression (log2-ratio):-3.1420107Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | tunicamycin study 2 (2ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- |
expO ovary cancer study 1 (endometrioid carcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):3.1133842Number of Samples:3 / 2
| Experimental | expO ovary cancer study 1 (endometrioid carcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |